|Articles|May 9, 2017
WIRB-Copernicus Acquires Again
WIRB-Copernicus Group (WCG) has announced the acquisition of MedAvante and ProPhase, and has named Dr. Jeffrey Litwin as CEO of the combined organization.
Advertisement
WIRB-Copernicus Group (WCG) has announced the acquisition of MedAvante and ProPhase, and has named Dr. Jeffrey Litwin as CEO of the combined organization. This acquisition provides WCG’s clients with a more comprehensive and integrated suite of study start-up solutions.
Read the full release
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Breaking the Efficacy Ceiling in IBD and Beyond
2
The Career They Didn't Train For: Rethinking Early-Career Burnout in Clinical Research
3
ACT Brief: Substance Versus Branding in Biotech Support, Site-Level Execution Gaps and Point-of-Care Data, and KCNT1-Targeted Pediatric Epilepsy Program
4
Why Clinical Trial Modernization Fails Without Point-of-Care Data: Q&A with Richard Graham, PhD, TruTechnologies
5